Erdafitinib inhibits the tumorigenicity of MDA-MB-231 triple-negative breast cancer cells by inducing TRIM25/ubiquitin-dependent degradation of FGFR4

Erdafitinib inhibits the tumorigenicity of MDA-MB-231 triple-negative breast cancer cells by inducing TRIM25/ubiquitin-dependent degradation of FGFR4

Abstract Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer (BC), characterized by limited treatment options and poor clinical outcomes. Aberrant FGFR signaling has been implicated in TNBC; however, the therapeutic potential of targeting FGFRs for TNBC treatment rema...

Full description

Saved in:
Bibliographic Details
Main Authors: Qing Luo, Li Zhang, Yue Hao, Chunwei Xu, Xiaojia Wang, Zhen Jia, Xiandong Xie, Zhihong Huang, Xiaomin Gao, Yu Chen, Xue Zhu, Jing Fang, Ke Wang, Yongxiang Yin
Format: Article
Language:English
Published: BMC 2025-07-01
Series:Breast Cancer Research
Subjects:
TNBC
Erdafitinib
FGFR1/4
TRIM25
Ubiquitination
Biomarker
Online Access:https://doi.org/10.1186/s13058-025-02086-7
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s13058-025-02086-7

Similar Items